

## Medical Policy



### Title: Steroid-Eluting Sinus Stents and Implants

<i>Related Policies:</i>	<ul style="list-style-type: none"> <li>▪ <i>Balloon Ostial Dilatation for Treatment of Chronic and Recurrent Acute Rhinosinusitis</i></li> </ul>
--------------------------	--

<b>Professional / Institutional</b>
Original Effective Date: July 25, 2021
Latest Review Date: April 23, 2026
Current Effective Date: April 23, 2026

**State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member's benefits, contact [Blue Cross and Blue Shield of Kansas Customer Service](#).**

**The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy.**

**The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice.**

**If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.**

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> <li>• With chronic rhinosinusitis who have undergone endoscopic sinus surgery</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>• Steroid-eluting sinus stents</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>• Standard management (including topical steroid, packing, and irrigation)</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>• Symptoms</li> <li>• Change in disease status</li> <li>• Morbid events</li> <li>• Treatment-related morbidity</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>• With recurrent sinonasal polyposis who have undergone endoscopic sinus surgery</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>• Steroid-eluting sinus stents</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>• Topical steroids alone</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>• Symptoms</li> <li>• Change in disease status</li> <li>• Morbid events</li> <li>• Treatment-related morbidity</li> </ul>

**DESCRIPTION**

Steroid-eluting sinus stents are devices used postoperatively following endoscopic sinus surgery (ESS) or for treatment of recurrent sinonasal polyposis following ESS. These devices maintain patency of the sinus openings in the postoperative period, and/or serve as a local drug delivery vehicle. Reducing postoperative inflammation and maintaining patency of the sinuses may be important in achieving optimal sinus drainage and may impact recovery from surgery and/or reduce the need for additional surgery.

**OBJECTIVE**

The objective of this review is to determine whether steroid-eluting sinus stents and implants improve the net health outcome in individuals with chronic rhinosinusitis or sinonasal polyposis after endoscopic sinus surgery. or as stand-alone treatment.

**BACKGROUND****Chronic Rhinosinusitis**

Chronic rhinosinusitis is an inflammatory sinus condition that has a prevalence between 1% and 5% in the U.S. population.<sup>1</sup>

**Treatment**

Endoscopic sinus surgery (ESS) is typically performed on patients with chronic rhinosinusitis unresponsive to conservative treatment. The surgery is associated with high rates of improvement in up to 90% of more appropriately selected patients. However, there are no high-quality randomized controlled trials (RCTs) comparing functional ESS with continued medical management or alternative treatment approaches. Because of the high success rates and minimally invasive approach, these procedures have rapidly increased in frequency, with an estimated 250,000 procedures performed annually in the United States.<sup>2</sup> They can be done either in the physician's office under local anesthesia or in the hospital setting under general anesthesia.

ESS involves the removal of small pieces of bone, polyps, and debridement of tissue within sinus cavities. There are a number of variations on the specific approach, depending on the disorders being treated and the preferences of the treating surgeon. For all procedures, there is substantial postoperative inflammation and swelling, and postoperative care is, therefore, a crucial component of ESS.

There are a number of postoperative treatment regimens, and the optimal regimen is uncertain. Options include saline irrigation, nasal packs, topical steroids, systemic steroids, topical decongestants, oral antibiotics, and/or sinus cavity debridement. Several RCTs have evaluated treatment options, but not all strategies have been rigorously evaluated.<sup>3,4,5,6</sup> A 2011 systematic review has evaluated the evidence for these therapies.<sup>2</sup> Reviewers concluded that the evidence was not strong for any of these treatments but that some clinical trial evidence supported improvements in outcomes. The strongest evidence supported use of nasal saline irrigation, topical nasal steroid spray, and sinus cavity debridement.

Some form of sinus packing is generally performed postoperatively. Simple dressings moistened with saline can be inserted manually following surgery. Foam dressings are polysaccharide substances that form a gel when hydrated and can be used as nasal packs for a variety of indications.<sup>7</sup> Middle meatal spacers are splint-like devices that prop open the sinus cavities post-ESS but are not designed for drug delivery. There is some RCT evidence that middle meatal spacers may reduce the formation of synechiae following ESS, although the available studies have significant heterogeneity in this outcome.<sup>8</sup>

### **Sinus Stents and Implants**

Implantable sinus stents and implants are another option for postoperative management following ESS. These implants are intended to stabilize the sinus openings and the turbinates, reduce edema, and/or prevent obstruction by adhesions. They can also be infused with medication delivered topically over an extended period of time, and this local delivery of medications may be superior to topical applications in the postoperative setting.

### **REGULATORY STATUS**

In 2011, the PROPEL® system (Intersect ENT, Menlo Park, CA) was approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process (P100044). This device is a self-expanding, bioabsorbable, steroid-eluting stent intended for use in the ethmoid sinus. It is placed via endoscopic guidance using a plunger included with the device. Steroids (mometasone furoate) are released over an approximate duration of 30 days. The device dissolves over several weeks and therefore does not require removal. In 2012, a smaller version of the PROPEL device, the PROPEL Mini Sinus Implant, was approved for use in patients older than age 18 years following ethmoid sinus surgery to maintain patency. In 2017, the PROPEL Contour was approved through a premarket approval supplement. The PROPEL Contour sinus implant is an adaptable implant that is designed to maximize drug delivery to the frontal and maxillary sinus.

SINUVA™ Sinus Implant (Intersect ENT, Inc., Menlo Park, CA) was initially approved in 1987. In 2017, the SINUVA Sinus Implant was approved with a new dose (1350 µg mometasone furoate) under a New Drug Application (NDA 209310). The corticosteroid is released over 90 days and the bioabsorbable polymers soften over this time. The implant is removed at Day 90 or earlier using standard surgical instruments. The SINUVA™ Sinus Implant is indicated for the treatment of nasal polyps in adult patients who have had ethmoid sinus surgery.

FDA product code: OWO

## POLICY

- A. Mometasone furoate sinus implants may be considered **medically necessary** in individuals for recurrent nasal polyp disease following ethmoid sinus surgery when the below criteria are met:
1. Over the age of 18 years old; **AND**
  2. Has had an inadequate response to a 3-month trial of TWO nasal corticosteroid sprays (i.e. mometasone, fluticasone, budesonide, or triamcinolone); **AND**
  3. Has had inadequate response, intolerance, or contraindication to a 14 day trial of an oral corticosteroid (i.e. prednisone, methylprednisolone, or dexamethasone); **AND**
  4. The administering physician is an Otolaryngologist (ENT)
- B. Greater than one Mometasone furoate sinus implant per nostril in a 12 month period is considered **experimental / investigational**.
- C. Steroid-eluting sinus stents and implants that do not meet criteria listed in policy item A are considered **experimental / investigational**.

## POLICY GUIDELINE

- A. Sinus stents are defined as implantable devices specifically designed to improve patency and/or deliver local medication. These devices are inserted under endoscopic guidance and are distinguished from sinus packing and variations on packing devices routinely employed after sinus surgery.
- B. Foam dressings, such as Sinu-Foam™, are used as nasal packs for a variety of conditions, including nosebleeds, and have also been used after endoscopic sinus surgery. They are considered different types of nasal packing.
- C. Middle meatal spacers are related but separate devices intended to maintain sinus patency post-endoscopic sinus surgery. They are splint-like devices inserted directly rather than under endoscopic guidance and do not have the capability of delivering local medication.

**Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.**

## RATIONALE

This evidence review was created using searches of the PubMed database. The most recent literature update was performed through December 31, 2025.

Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life, and ability to function including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and

whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

RCTs are important in the evaluation of sinus implants as an adjunct to endoscopic sinus surgery (ESS) to adequately compare implantable stents with alternative treatment regimens and to minimize the effects of confounders on outcomes. Case series and trials without control groups offer little in the way of relevant evidence, because improvement in symptoms is expected after ESS and because there are multiple clinical and treatment variables that may confound outcomes.

## **STEROID-ELUTING STENTS AS AN ADJUNCT TO ENDOSCOPIC SINUS SURGERY**

### **Clinical Context and Therapy Purpose**

The purpose of a steroid-eluting sinus stent in individuals who have chronic rhinosinusitis (CRS) who have endoscopic sinus surgery (ESS) is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

### ***Populations***

The population of interest is individuals who have ESS for CRS.

### ***Interventions***

The therapy being considered is a bioabsorbable steroid-eluting sinus stent (eg, PROPEL Sinus Stent, PROPEL Mini Sinus Stent, PROPEL Countour Sinus Stent) for post-operative care following ESS.

### ***Comparators***

The most relevant comparison for sinus stents is unclear because there is no standardized optimal postoperative treatment regimen. Ideally, the "standard care" comparison group should include some form of packing, intranasal steroids, and irrigation. An important consideration in evaluating controlled trials is that the control arm may not be treated with optimal intensity, thereby leading to a bias in favor of the device. For example, a study design that compares a steroid-eluting stent with a non-steroid-eluting stent will primarily evaluate the efficacy of steroids when delivered by the device but will not evaluate the efficacy of a stent itself. If the control group does not receive topical or oral steroids postoperatively, then this might constitute

undertreatment in the control group and result in a bias favoring the treatment group. Another concern is comparison of the efficacy of a drug with the efficacy of a drug delivery system. For example, if a steroid-eluting spacer is compared with a control of saline irrigation alone, it will be difficult to separate the efficacy of the drug itself (steroids) from the drug delivery system (stent).

### **Outcomes**

The Perioperative Sinus Endoscopy score sums the combined scores determined from middle turbinate position, middle meatal status, ethmoid cavity appearance, as well as secondary sinus blockage (frontal and sphenoid). Each category is scored from 0-2, with 0 being not present, 1 as partially present, and 2 being fully present. The highest total score is 16, with scores ranging from 18-20 when the frontal and sphenoid sinuses are also included. The higher the score, the worse the status of the nasal cavity.

Post-ESS synechiae formation, the Sino-Nasal Outcome Test (SNOT-22) Questionnaire, and the Rhinosinusitis Disability Index may also be used to evaluate perioperative outcomes.

A beneficial outcome would be an improvement in symptoms.

A harmful outcome would be adverse events from the implantable stents.

The PROPEL series of sinus stents are bioabsorbable and elute steroids for 30 days. Therefore, outcomes should be assessed within 30 days.

### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.
- Studies evaluating steroid-eluting sinus stents not approved for use in the US were excluded.

### **Review of Evidence**

The literature consists of randomized trials, single-arm case series, and systematic reviews of these studies. The following is a summary of the key findings to date.

### **Systematic Reviews**

A 2015 Cochrane review addressed steroid-eluting sinus stents for improving CRS symptoms in individuals undergoing ESS.<sup>9</sup> Study eligibility criteria were RCTs that compared the effects of steroid-eluting sinus stents with non-steroid-eluting sinus stents, nasal packing, or no treatment in adults with CRS who underwent ESS. After an initial search, 21 RCTs were identified, including the RCTs reported by Murr et al (2011)<sup>10</sup>, and Marple et al (2012)<sup>11</sup>, (described below). None of the trials met authors' inclusion criteria. Reviewers concluded that there was no evidence from high-quality RCTs to demonstrate the benefits of steroid-eluting stents.

Zamali et al (2025 ) evaluated the efficacy of steroid-eluting sinus stents on postoperative outcomes in CRS patients undergoing ESS.<sup>12</sup> Seven RCTs (N=1122) were included; 6 of these trials used the contralateral sinus as the control group, while one was sham-controlled. Results suggested that steroid-eluting stents significantly reduced adhesion formation (odds ratio [OR], 0.28; 95% confidence interval [CI], 0.14 to 0.56), mucosal inflammation (mean difference [MD], -13.09; 95% CI, -18.22 to -7.97), polyp reformation (OR, 0.31; 95% CI, 0.22 to 0.44), and the need for additional oral steroids (OR, 0.44; 95% CI, 0.25 to 0.78) or surgery (OR, 0.25; 95% CI, 0.12 to 0.50) relative to control group at 30 days post-surgery. Heterogeneity across all outcomes was 0%, and the authors determined there to be a moderate quality of evidence according to GRADE criteria. Improvements persisted for up to 90 days for some outcomes.

### Randomized Controlled Trials

RCTs are shown in Tables 1 and 2. There are 4 RCTs of the PROPEL, PROPELMini, and PROPEL Contour steroid-eluting sinus stents sponsored by the device manufacturer (Intersect ENT [now a subsidiary of Medtronic]). These trials used an inpatient control design, with each patient receiving a drug-eluting stent on 1 side and a non-drug-eluting stent or medical treatment on the other via random assignment. A fifth RCT not sponsored by the manufacturer also had patients serve as their own control with stent placement in right or left frontal sinus and steroid rinse to both sinus sides.

The 2 trials of PROPEL for the ethmoid sinus had similar designs.<sup>10,11</sup> Both compared an implant that is steroid-eluting with an identical non-steroid-eluting implant. Thus, these trials tested the value of drug delivery via a stent but did not test the value of a stent itself versus treatment without a stent. The primary efficacy outcome in Murr et al. (2011) was degree of inflammation rated by the treating physician.<sup>10</sup> In Marple et al (2012) the primary outcome was reduction in the need for postoperative interventions at day 30 postprocedure.<sup>11</sup> A panel of 3 independent experts, blinded to treatment assignment and clinical information, viewed the endoscopic results and determined whether an intervention was indicated. The need for postoperative intervention by expert judgment was found in 33.3% of patients in the steroid-eluting arm and in 46.9% in the non-steroid-eluting arm (p=.028). The reduction in interventions was primarily driven by a 52% reduction in lysis of adhesions (p=.005). The primary safety hypothesis was met because there were no cases of clinically significant increases in ocular pressure recorded over the 90-day period post procedure.

The RCTs by Smith et al (2016) and Luong et al (2017), implanted either a PROPEL Mini Sinus Implant or a PROPEL Contour Sinus Implant in the frontal sinus with a control of surgery alone on the contralateral side.<sup>13,14</sup> The primary outcome was the need for post-operative intervention (eg, surgery or steroids) determined by an independent blinded physician. Both trials showed a reduction in the need for additional surgical intervention by approximately 22%, with no adverse effects of treatment. The number needed to treat was 4.7 to prevent 1 patient from undergoing postoperative intervention.<sup>14</sup> No stent-related adverse events were noted.

In the non-sponsored, single-center RCT by Fieux et al (2025), all patients received standardized postoperative care including high volume nasal saline irrigation with budesonide (0.5 mg/2 mL) with one sinus side randomly assigned to stent implantation with either the PROPELMini or PROPEL Contour.<sup>15</sup> The primary outcome was stent patency with outcomes assess at 1, 3, 12,

and 24 weeks postoperatively. Frontal sinus patency was similar between groups at all time points.

**Table 1. Summary of Key RCT Characteristics**

Study; Trial	Countries	Sites	Participants	Interventions	
				Active	Comparator
Murr et al (2011) <sup>10</sup> ,	US	4	38 patients with refractory CRS	Unilateral PROPEL steroid-eluting stent in the ethmoid sinus	Non-drug-eluting stent on the other contralateral side
Marple et al (2012) <sup>11</sup> , (ADVANCE II)	US	11	105 patients with refractory CRS	Unilateral PROPEL steroid-eluting stent in the ethmoid sinus	Non-drug-eluting stent on the contralateral side
Smith et al (2016) <sup>13</sup> ,	US	11	80 patients with CRS who were scheduled to undergo primary or revision bilateral frontal sinusotomy	Unilateral PROPEL Mini Sinus Implant in the frontal sinus	Surgery alone on the contralateral side
Luong et al (2017) <sup>14</sup> ,	US	12	80 patients with CRS who were scheduled to undergo primary or revision bilateral frontal sinusotomy	Unilateral PROPEL Contour Sinus Implant in the frontal sinus	Surgery alone on the contralateral side
Fieux et al (2025) <sup>15</sup> ,	NR	1	59 adult patient with CRS and nasal polyps undergoing endoscopic sinus surgery of both frontal sinuses	Unilateral PROPEL Contour or PROPELMini Sinus Implant in the frontal sinus	Surgery alone on the contralateral side

ADVANCE II: a prospective, randomized study assessing safety and efficacy of bioabsorbable steroid-releasing sinus implants; CRS: chronic rhinosinusitis; RCT: randomized controlled trial.

**Table 2. Summary of Key RCT Results**

<b>Study</b>	<b>Primary Outcome Measure</b>	<b>Polypoid Changes</b>	<b>Adhesions/Scarring</b>		<b>Implant-Related Adverse Events</b>
Murr et al (2011) <sup>10</sup> ,	<b><i>Degree of Inflammation at 21 Days Post-Procedure (100 mm VAS)</i></b>				
N	37	37			
PROPEL steroid-eluting Stent		18.4%	5.3%		
Non-steroid-eluting stent		36.8%	21.1%		
Diff	18 points				
p-value	NR	.039	.03		
Marple et al (2012) <sup>11</sup> ,	<b><i>Need for Post-Operative Intervention Determined by 3 Independent Reviewers</i></b>				
N	91				
PROPEL steroid-eluting Stent	33.3%				
Non-steroid-eluting stent	46.9%				
Diff	13.6%				
p-value	0.028				
Smith et al (2016) <sup>13</sup> ,	<b><i>Need for Post-Operative Intervention at 30 Days (Independent Reviewer) n (%)</i></b>	<b><i>Need for Post-Operative Intervention at 90 Days</i></b>		<b><i>Occlusion/Restenosis Rate at Day 30</i></b>	

<b>Study</b>	<b>Primary Outcome Measure</b>	<b>Polypoid Changes</b>	<b>Adhesions/Scarring</b>		<b>Implant-Related Adverse Events</b>
N	67 (adequate video for independent review)	79			
PROPEL mini-sinus steroid-eluting stent	26 (38.8%)			16 (21.1%)	none
SOC without a stent	42 (62.7%)			35 (46.1%)	
p-value	.007	.013	.023	<.001	
Luong et al (2017) <sup>14</sup> ,	<b>Need for Post-Operative Intervention at 30 Days (Independent Reviewer) n (%)</b>	<b>Need for Surgical Intervention at 30 Days (Independent Reviewer) n (%)</b>		<b>Occlusion/Restenosis Rate at Day 90</b>	
N	61	58		69	
PROPEL Contour steroid-eluting stent	7 (11.5)	4 (6.9)		16 (23.2)	
SOC without a stent	20 (32.8)	15 (25.9)		28 (40.6)	
Diff (95% CI)	21.3% (35.1% to 7.6%)	19.0% (32.8% to 5.1%)		-17.4% (-28.6% to -6.1%)	
NNT	4.7				
Summary Values	Range 13.6% to 23.9%				
Fieux et al (2025) <sup>15</sup> ,	<b>Frontal Sinus Patency at 1 Week</b>	<b>Frontal Sinus Patency at 6 Months</b>		<b>Additional Surgical Treatment at 6 Months</b>	<b>Additional Medical Treatment at 6 Months</b>
N	57	48	48	48	48
PROPEL Contour or PROPELMini steroid-eluting stent	96.5%	87.5%	12.5%	0%	6.2%
SOC without a stent	96.5%	85.4%	16.7%	0%	6.2%

CI: confidence interval; Diff: difference; NNT: number needed to treat; NR: not reported; OR, odds ratio; RCT: randomized controlled trial; SOC: standard of care; VAS: visual analog scale.

Limitations in relevance and in design and conduct are shown in Tables 3 and 4. The primary limitations for the studies by Murr et al (2011) and Marple et al (2012) on the PROPEL implant in the ethmoid sinus was whether the comparator had received the optimal treatment in terms of packing, intranasal steroids, and irrigation. For the studies by Smith et al (2016) and Luong et al (2017), there was a high percentage of patients who were not able to be evaluated due to video quality.

**Table 3. Study Relevance Limitations**

Study	Population <sup>a</sup>	Intervention <sup>b</sup>	Comparator <sup>c</sup>	Outcomes <sup>d</sup>	Follow-Up <sup>e</sup>
Murr et al (2011) <sup>10</sup> ,			3. The comparator may not have received the optimal treatment (some form of packing, intranasal steroids, and irrigation)		
Marple et al (2012) <sup>11</sup> ,			3. The comparator may not have received the optimal treatment (some form of packing, intranasal steroids, and irrigation)		
Smith et al (2016) <sup>13</sup> ,					
Luong et al (2017) <sup>14</sup> ,					
Fieux et al (2025) <sup>15</sup> ,	5. Few demographic characteristics reported				

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.

<sup>b</sup> Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest (e.g., proposed as an adjunct but not tested as such); 5: Other.

<sup>c</sup> Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.

<sup>d</sup> Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. Incomplete reporting of harms; 4. Not establish and validated measurements; 5. Clinically significant difference not prespecified; 6. Clinically significant difference not supported; 7. Other.

<sup>e</sup> Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.

**Table 4. Study Design and Conduct Limitations**

Study	Allocation <sup>a</sup>	Blinding <sup>b</sup>	Selective Reporting <sup>c</sup>	Data Completeness <sup>d</sup>	Power <sup>e</sup>	Statistical <sup>f</sup>
Murr et al (2011) <sup>10</sup> ,		3. Outcome assessed by treating physician				
Marple et al (2012) <sup>11</sup> ,						
Smith et al (2016) <sup>13</sup> ,			2. Incomplete reporting of secondary outcomes	1. 12 (17%) patients did not have independent review at 30 days due to suboptimal video quality.		
Luong et al (2017) <sup>14</sup> ,				1. 19 (24%) patients did not have independent review at 30 days due to suboptimal video quality.		
Fieux et al (2025) <sup>15</sup> ,						3,4, Incomplete reporting of comparative treatment effects, CI, and p-values

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

<sup>b</sup> Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

<sup>c</sup> Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

<sup>d</sup> Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

<sup>e</sup> Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

<sup>f</sup> Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p-values not reported; 4. Comparative treatment effects not calculated.

### Nonrandomized Comparative Studies

The largest nonrandomized study identified was reported by Xu et al (2016).<sup>16</sup> It evaluated post-ESS synechia formation among 146 patients (252 nasal cavities) treated with a steroid-eluting absorbable spacer and 128 patients (233 nasal cavities) treated with a nonabsorbable spacer.

Eligible patients included those who underwent ESS (at minimum, maxillary antrostomy, and anterior ethmoidectomy) for CRS with or without nasal polyps and were treated with a sinus spacer. Rates of synechiae formation at 1 month postoperatively did not differ significantly between groups (5 [2.0%] nasal cavities in the absorbable stent group vs. 13 [5.6%] nasal cavities in the nonabsorbable spacer group).

### **Section Summary: Steroid-Eluting Stents as an Adjunct to Endoscopic Sinus Surgery**

The most direct evidence relating to use of steroid-eluting nasal stents as an adjunct to ESS comes from 5 RCTs comparing steroid-eluting stents with either a non-steroid-eluting stent or medical management. The need for post-operative intervention at 30 days in the manufacturer-sponsored trials was reduced by 14% to 24%, translating to a number needed to treat of 4.7 or more. Three of these trials used blinded assessors to evaluate postimplantation sinus changes, an important strength, but the trials had potentials for bias. The findings from systematic reviews and meta-analyses are mixed. A Cochrane review reported insufficient high-quality evidence to assess the intervention, while a meta-analysis identified benefits of steroid-eluting stents compared to a control intervention, including reduced adhesion, mucosal inflammation, polyp recurrence, need for oral steroids post-surgery, and additional surgical procedures at 30 days follow-up. To most accurately evaluate the benefit from PROPEL devices it is important to ensure that the comparison group is not undertreated (ie, receives some form of packing, intranasal steroids, and irrigation), and a study not sponsored by the manufacturer required irrigation with steroid solution; however, that trial failed to find improved outcomes with steroid-eluting stents but lacked sufficient sample size to draw conclusions.

## **STEROID-ELUTING IMPLANTS FOR RECURRENT POLYPOSIS**

### **Clinical Context and Therapy Purpose**

The purpose of steroid-eluting implants in individuals who have recurrent polyposis is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals with recurrent polyposis after ESS.

### ***Interventions***

The therapy being considered is a steroid-eluting sinus implant (eg, SINUVA).

This implant is bioresorbable and softens over time, but needs to be removed by 90 days.

### ***Comparators***

A sham treatment may be used to determine whether active treatment reduces the need for ESS.

### ***Outcomes***

The general outcomes of interest are symptoms, anatomic outcomes, and need for additional ESS. These outcomes may be measured by the nasal obstruction/congestion score change (scale 0–3), polyp grade change (scale 0 to 8), ethmoid sinus obstruction change (scale 0–100), and the percentage of patients still indicated for repeat sinus surgery.

A beneficial outcome would be an improvement in symptoms and reduction in repeat ESS.

A harmful outcome would be adverse events from the implant.

The steroid-eluting implants are kept in place for up to 90 days. Relevant outcomes would be measured at 90 days to evaluate the short-term effects of the treatment and at 1 or 2 years to evaluate the durability of this treatment.

### Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.
- Studies evaluating steroid-eluting sinus stents not approved for use in the US were excluded.

### Review of Evidence

Two sham-controlled RCTs, RESOLVE (A Randomized, Controlled, Blinded Study of Bioabsorbable Steroid-eluting Sinus Implants for In-office Treatment of Recurrent Sinonasal Polyposis) and RESOLVE II (A Phase 3 Trial of Mometasone Furoate Sinus Implants for Chronic Sinusitis with Recurrent Nasal Polyps) with a total of 400 patients have addressed outcomes after placement of steroid-eluting absorbable sinus stents in the office setting due to recurrent or persistent nasal polyposis after ESS (see Tables 5 and 6).<sup>17,18,19</sup>

In RESOLVE, for endoscopically measured outcomes, at 90 days of follow-up, the treatment group had a greater reduction in polyp grade than the control group (-1.0 vs. -0.1;  $p=.016$ ) and a greater reduction in percent ethmoid obstruction on a 100-mm VAS (-21.5 mm vs. 1.3 mm;  $p=.001$ ), both respectively. For patient-reported outcomes, there were no significant differences in change in nasal obstruction/congestion scores between groups. Six-month outcomes from RESOLVE were reported by Forwith et al in 2016. Differences in polyp grade and ethmoid obstruction scores remained significantly improved in the intervention group at 6 months, but the difference between groups in patient-reported symptom scores was not statistically significant at 6 months (See Table 6).<sup>19</sup> In RESOLVE II the implant group showed significant reductions in nasal congestion, polyp grade, and ethmoid obstruction at 90 days compared to sham controls. Out of 200 patients treated with the implant, 39% were indicated for sinus surgery at 3 months compared to 63.3% of controls ( $p<.001$ ).

**Table 5. Summary of Key RCT Characteristics**

Study; Trial	Countries	Sites	Dates	Participants	Interventions	
					Active	Comparator
Han et al (2014);	US	18	2013-2014	100 patients with recurrent nasal polyposis after ESS who had	53 patients who received	47 patients who received

Study; Trial	Countries	Sites	Dates	Participants	Interventions	
Forwith et al (2016) <sup>17,19</sup> ; RESOLVE				chronic rhinosinusitis, had undergone prior bilateral total ethmoidectomy more than 3 months earlier, had endoscopically confirmed recurrent bilateral ethmoid sinus obstruction due to polyposis that was refractory to medical therapy, and were considered candidates for repeat surgery based on the judgment of the surgeon and patient.	office-based placement of a mometasone-eluting nasal stent	sham treatment
Kern et al (2018) <sup>18</sup> ; RESOLVE II	US	34	2014-2016	300 adults with refractory chronic rhinosinusitis with nasal polyps who were candidates for repeat surgery. To be indicated for repeat ESS, a patient had to: (1) be using intranasal corticosteroid daily ; (2) receive at least 1 course of high-dose steroid therapy or refused such therapy due to side effects within the past 1 year; (3) continue to have moderate-to-severe symptoms of nasal obstruction/congestion; and (4) have endoscopic evidence of bilateral ethmoid sinus obstruction due to polyposis.	201 patients who received a SINUVA(TM) mometasone-eluting bioabsorbable nasal stent	99 patients who received sham treatment consisting of insertion and removal of implants

RESOLVE: a randomized, controlled, blinded study of bioabsorbable steroid-eluting sinus implants for in-office treatment of recurrent sinonasal polyposis; RESOLVE II: a phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps; ESS: endoscopic sinus surgery; RCT: randomized controlled trial.

**Table 6. Summary of Key RCT Results**

Study	Nasal obstruction/congestion score change (scale 0–3) at 90 days	Nasal obstruction/congestion score change (scale 0–3) at 6 months	Change in Polyp Grade at 90 Days (scale 0 to 8)	Change in Polyp Grade at 6 Months (scale 0 to 8)	Reduction in Ethmoid Obstruction (scale 100) at 90 Days	Reduction in Ethmoid Obstruction (scale 100) at 6 months	Patients Indicated for Sinus Surgery at 3 months n (%)
Han et al (2014); Forwith et al (2016) <sup>17</sup> ;							

Study	Nasal obstruction/congestion score change (scale 0–3) at 90 days	Nasal obstruction/congestion score change (scale 0–3) at 6 months	Change in Polyp Grade at 90 Days (scale 0 to 8)	Change in Polyp Grade at 6 Months (scale 0 to 8)	Reduction in Ethmoid Obstruction (scale 100) at 90 Days	Reduction in Ethmoid Obstruction (scale 100) at 6 months	Patients Indicated for Sinus Surgery at 3 months n (%)
<sup>19,;</sup> RESOLVE							
Drug-eluting nasal implant		-1.06	-1.0	-0.071	-21.5 mm	-17.1 mm	47%
Sham		-0.44	-0.1	0.02	1.3 mm	-5.6 mm	77%
P-value		.124	.016	.018	.001	.010	NR
Kern et al (2018) <sup>18,;</sup> RESOLVE II							
Drug-eluting nasal implant mean (SD)	-0.80 (0.73)		-0.56 (1.06)		-11.3 (18.1)		78/200 (39.0%)
Sham mean (SD)	-0.56 (0.62)		-0.15 (0.91)		-1.9 (14.4)		62/98 (63.3%)
Diff or OR (95% CI)	-0.23 (-0.39 to -0.06)		-0.35 (-0.60 to -0.09)		-7.96 (-12.10 to -3.83)		2.69 (1.63 to 4.44)
P-value	.007		.007		<.001		<.001

RESOLVE: a randomized, controlled, blinded study of bioabsorbable steroid-eluting sinus implants for in-office treatment of recurrent sinonasal polyposis; RESOLVE II: a phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps; CI: confidence interval; Diff: difference; NR: not reported; OR: odds ratio; RCT: randomized controlled trial; SD: standard deviation.

Limitations in relevance, design, and conduct are shown in Tables 7 and 8. A major limitation of

RESOLVE II was the short duration of follow-up to determine the durability of the treatment. In addition, there is a potential for bias since outcomes were evaluated by the treating physician.

**Table 7. Study Relevance Limitations**

Study	Population <sup>a</sup>	Intervention <sup>b</sup>	Comparator <sup>c</sup>	Outcomes <sup>d</sup>	Follow-Up <sup>e</sup>
Han et al (2014); Forwith et al (2016) <sup>17,19</sup> ; RESOLVE					1. The 6-month follow-up is insufficient to evaluate the durability of this treatment.
Kern et al (2018) <sup>18</sup> ; RESOLVE II					1. The 90-day follow-up is insufficient to evaluate the durability of this treatment.

RESOLVE: a randomized, controlled, blinded study of bioabsorbable steroid-eluting sinus implants for in-office treatment of recurrent sinonasal polyposis; RESOLVE II: a phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.

<sup>b</sup> Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest (e.g., proposed as an adjunct but not tested as such); 5. Other.

<sup>c</sup> Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.

<sup>d</sup> Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3.

Incomplete reporting of harms; 4. Not establish and validated measurements; 5. Clinically significant difference not prespecified; 6. Clinically significant difference not supported; 7. Other.

<sup>e</sup> Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.

**Table 8. Study Design and Conduct Limitations**

Study	Allocation <sup>a</sup>	Blinding <sup>b</sup>	Selective Reporting <sup>c</sup>	Data Completeness <sup>d</sup>	Power <sup>e</sup>	Statistical <sup>f</sup>
Han et al (2014); Forwith et al (2016) <sup>17,19</sup> ; RESOLVE		3. Outcomes were assessed by the treating physician				3. Statistics were not reported for some outcome measures.
Kern et al (2018) <sup>18</sup> ; RESOLVE II		3. Polyp grade and sinus obstruction were assessed by the treating physician				

RESOLVE: a randomized, controlled, blinded study of bioabsorbable steroid-eluting sinus implants for in-office treatment of recurrent sinonasal polyposis; RESOLVE II: a phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear;

4. Inadequate control for selection bias.

<sup>b</sup> Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

<sup>c</sup> Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

<sup>d</sup> Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

<sup>e</sup> Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

<sup>f</sup> Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

### **Section Summary: Steroid-Eluting Stents for Recurrent Polyposis**

Two RCTs evaluated the use of steroid-eluting nasal implants for recurrent or persistent nasal polyposis after ESS, which demonstrated improvements in polyp grade and ethmoid obstruction. Strengths of the trials included use of sham control and adequate power for the primary outcome. However, the trials had a high risk of bias due to unblinded outcome assessment. Although avoidance of repeat ESS and oral steroids may be relevant outcomes for this indication, it would be more important if decisions about repeat ESS or other treatments were standardized and, in the trial setting, if decisions were prespecified or made by a clinician blinded to treatment group.

### **SUPPLEMENTAL INFORMATION**

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

### **Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

### **American Academy of Otolaryngology-Head and Neck Surgery**

In 2023, the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) issued a position statement on the use of drug-eluting sinus implants for the management of mucosal inflammation of the paranasal sinuses. This statement was not based on a systematic review of the evidence.

"The AAO-HNS considers drug-eluting implants in the paranasal sinuses as a proven and effective therapeutic option for mucosal inflammation."<sup>20</sup>

The recommendation states, "Multiple studies have demonstrated the efficacy and safety of drug-eluting implants in controlling sinonasal inflammation. Clinical evidence regarding the use of drug-eluting implants after sinus surgery has particularly shown enhanced wound healing through the reduction of both scar formation and anatomic obstruction."

### American Rhinologic Society

In 2023, the American Rhinologic Society (ARS) issued a position statement on the utilization of drug-eluting implants into the sinus cavities. This position statement was not based on a systematic review of the evidence.:

"ARS feels strongly that drug-eluting implants should in no way be considered investigational and should be available to patients, when selected by the physician, in order to maximize outcomes." <sup>21</sup>,

The recommendation notes, "There continues to be a growing level of high-quality evidence on the safety and efficacy of drug-eluting implants in the paranasal sinuses. These studies have demonstrated cost effectiveness as well as improvement of patient centered outcomes by reducing inflammation, maintaining ostial patency, decreasing scarring, and preventing middle turbinate lateralization while limiting the need for administration of oral steroids.."

### International Consensus Statement on Allergy and Rhinology

In 2021, the International Consensus Statement on Allergy and Rhinology for rhinosinusitis was updated and included the following recommendation:

"Corticosteroid-eluting implants can be considered as an option in a previously operated ethmoid cavity with recurrent nasal polyposis." <sup>22</sup>,

The recommendation noted, "Corticosteroid eluting implants have been shown to have beneficial impact on ethmoid polyposis and obstruction, and 1 study has shown them to be cost-effective in preventing revision ESS. Experience is early and although evidence is high level, only short-term outcomes are currently available."

### U.S. Preventive Services Task Force Recommendations

Not applicable.

### Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 9.

**Table 9. Summary of Key Trials**

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT03607175	Randomized Clinical Control Trial Comparing the Effects of a Steroid Eluting Implant Versus Triamcinolone-impregnated Carboxymethylcellulose Foam on the Postoperative Clinic Experience in Patients That Underwent Functional Endoscopic Surgery for Nasal Polyposis	30	Dec 2025
NCT05925985 <sup>a</sup>	Propel Drug-Eluting Sinus Stent Family	200	Dec 2025
NCT06198894	Study on the Efficacy of in Office Steroid-eluting Sinus Stent Implantation in Chronic Rhinosinusitis Patients With Uncontrolled Postoperative Symptoms	96	Apr 2026

NCT: national clinical trial.

<sup>a</sup> Denotes industry-sponsored or cosponsored trial.

**CODING**

**The following codes for treatment and procedures applicable to this policy are included below for informational purposes. This may not be a comprehensive list of procedure codes applicable to this policy.**

**Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.**

**The code(s) listed below are medically necessary ONLY if the procedure is performed according to the "Policy" section of this document.**

<b>CPT/HCPCS</b>	
31237	Nasal/sinus endoscopy, surgical; with biopsy, polypectomy or debridement (separate procedure)
31299	Unlisted procedure, accessory sinuses
C1874	Stent, coated/covered, with delivery system
C2625	Stent, non-coronary, temporary, with delivery system
J7402	Mometasone furoate sinus implant, (sinuva), 10 micrograms
S1091	Stent, non-coronary, temporary, with delivery system (propel)

<b>REVISIONS</b>	
07-25-2021	Policy added to the bcbsks.com web site.
05-09-2022	Changed Title to "Steroid-Eluting Sinus Stents and Implants"
	Updated Description Section
	Updated Policy Section <ul style="list-style-type: none"> <li>▪ Section C changed "Sinus Implants" to read "Steroid-eluting sinus stents and implants" that do not meet criteria listed in policy item A are considered experimental / investigational.</li> </ul>
	Updated Rationale Section
	Updated Coding Section <ul style="list-style-type: none"> <li>▪ Removed Code C9122</li> <li>▪ Removed Coding bullet <ul style="list-style-type: none"> <li>○ To report endoscopic placement of a drug-eluting implant in the ethmoid sinus in conjunction with biopsy, polypectomy, or debridement, use CPT 31237.</li> </ul> </li> </ul>
	Updated References Section
03-28-2023	Updated Description Section
	Updated Rationale Section
	Updated Coding Section <ul style="list-style-type: none"> <li>▪ Removed ICD-10 Diagnoses box</li> </ul>
	Updated References Section
03-26-2024	Updated Description Section
	Updated Rationale Section
	Updated References Section
03-27-2025	Updated Description Section

<b>REVISIONS</b>	
	Updated Rationale Section
	Updated References Section
Posted 03-24-2026	Updated Description Section
Effective 04-23-2026	Update Policy Section <ul style="list-style-type: none"> <li>▪ Section B: "Greater than one Mometasone furoate sinus implant per nostril in a 12 month period is considered" <ul style="list-style-type: none"> <li>○ Changed from not medically necessary to experimental / investigational</li> </ul> </li> </ul>
	Updated Rationale Section
	Updated Reference Section

## REFERENCES

1. Sedaghat AR. Chronic Rhinosinusitis. Am Fam Physician. Oct 15 2017; 96(8): 500-506. PMID 29094889
2. Rudmik L, Soler ZM, Orlandi RR, et al. Early postoperative care following endoscopic sinus surgery: an evidence-based review with recommendations. Int Forum Allergy Rhinol. 2011; 1(6): 417-30. PMID 22144050
3. Berlucchi M, Castelnuovo P, Vincenzi A, et al. Endoscopic outcomes of resorbable nasal packing after functional endoscopic sinus surgery: a multicenter prospective randomized controlled study. Eur Arch Otorhinolaryngol. Jun 2009; 266(6): 839-45. PMID 18946677
4. Côté DW, Wright ED. Triamcinolone-impregnated nasal dressing following endoscopic sinus surgery: a randomized, double-blind, placebo-controlled study. Laryngoscope. Jun 2010; 120(6): 1269-73. PMID 20513050
5. Freeman SR, Sivayoham ES, Jepson K, et al. A preliminary randomised controlled trial evaluating the efficacy of saline douching following endoscopic sinus surgery. Clin Otolaryngol. Oct 2008; 33(5): 462-5. PMID 18983380
6. Rotenberg BW, Zhang I, Arra I, et al. Postoperative care for Samter's triad patients undergoing endoscopic sinus surgery: a double-blinded, randomized controlled trial. Laryngoscope. Dec 2011; 121(12): 2702-5. PMID 21997904
7. Rudmik L, Mace J, Mechor B. Effect of a dexamethasone Sinu-Foam™ middle meatal spacer on endoscopic sinus surgery outcomes: a randomized, double-blind, placebo-controlled trial. Int Forum Allergy Rhinol. 2012; 2(3): 248-51. PMID 22253199
8. Lee JM, Grewal A. Middle meatal spacers for the prevention of synechiae following endoscopic sinus surgery: a systematic review and meta-analysis of randomized controlled trials. Int Forum Allergy Rhinol. Nov 2012; 2(6): 477-86. PMID 22648984
9. Huang Z, Hwang P, Sun Y, et al. Steroid-eluting sinus stents for improving symptoms in chronic rhinosinusitis patients undergoing functional endoscopic sinus surgery. Cochrane Database Syst Rev. Jun 10 2015; 2015(6): CD010436. PMID 26068957
10. Murr AH, Smith TL, Hwang PH, et al. Safety and efficacy of a novel bioabsorbable, steroid-eluting sinus stent. Int Forum Allergy Rhinol. 2011; 1(1): 23-32. PMID 22287304
11. Marple BF, Smith TL, Han JK, et al. Advance II: a prospective, randomized study assessing safety and efficacy of bioabsorbable steroid-releasing sinus implants. Otolaryngol Head Neck Surg. Jun 2012; 146(6): 1004-11. PMID 22301107
12. Zamaili AM, Kueh YC, Mohamad S, et al. The impact of middle meatal steroid-eluting implants on the postoperative outcomes of chronic rhinosinusitis: A systematic review and meta-analysis. Eur Ann Otorhinolaryngol Head Neck Dis. Jan 2025; 142(1): 26-37. PMID 38521652

13. Smith TL, Singh A, Luong A, et al. Randomized controlled trial of a bioabsorbable steroid-releasing implant in the frontal sinus opening. *Laryngoscope*. Dec 2016; 126(12): 2659-2664. PMID 27363723
14. Luong A, Ow RA, Singh A, et al. Safety and Effectiveness of a Bioabsorbable Steroid-Releasing Implant for the Paranasal Sinus Ostia: A Randomized Clinical Trial. *JAMA Otolaryngol Head Neck Surg*. Jan 2018; 144(1): 28-35. PMID 29098299
15. Fieux M, Noel J, Roozdar P, et al. Comparing Efficacy of Steroid Irrigation + Steroid-Eluting Sinus Stent Versus Steroid Irrigation Alone for Maintaining Frontal Sinus Patency After Sinus Surgery: A Randomized Controlled Trial. *Int Forum Allergy Rhinol*. May 2025; 15(5): 513-523. PMID 39778085
16. Xu JJ, Busato GM, McKnight C, et al. Absorbable Steroid-Impregnated Spacer After Endoscopic Sinus Surgery to Reduce Synechiae Formation. *Ann Otol Rhinol Laryngol*. Mar 2016; 125(3): 195-8. PMID 26391092
17. Han JK, Forwith KD, Smith TL, et al. RESOLVE: a randomized, controlled, blinded study of bioabsorbable steroid-eluting sinus implants for in-office treatment of recurrent sinonasal polyposis. *Int Forum Allergy Rhinol*. Nov 2014; 4(11): 861-70. PMID 25266981
18. Kern RC, Stolovitzky JP, Silvers SL, et al. A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps. *Int Forum Allergy Rhinol*. Apr 2018; 8(4): 471-481. PMID 29350840
19. Forwith KD, Han JK, Stolovitzky JP, et al. RESOLVE: bioabsorbable steroid-eluting sinus implants for in-office treatment of recurrent sinonasal polyposis after sinus surgery: 6-month outcomes from a randomized, controlled, blinded study. *Int Forum Allergy Rhinol*. Jun 2016; 6(6): 573-81. PMID 26992115
20. American Academy of Otolaryngology-Head and Neck Surgery. Position Statement: Drug-Eluting Sinus Implants. January 17, 2023; <https://www.entnet.org/resource/position-statement-eluting-implants/>. Accessed December 27, 2025.
21. American Rhinologic Society. ARS Position Statement: Criteria for Drug-Eluting Implants. January 28, 2023; <https://www.entnet.org/resource/position-statement-eluting-implants/>. Accessed December 30, 2025.
22. Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. *Int Forum Allergy Rhinol*. Mar 2021; 11(3): 213-739. PMID 33236525

## OTHER REFERENCES

1. Blue Cross and Blue Shield of Kansas Otolaryngology Liaison Committee Consent Ballot, June 2021.
2. Blue Cross and Blue Shield of Kansas Otolaryngology Liaison Committee, May 2020, July 2021, January 2022, May 2023.